# Systemic anti-cancer therapy for advanced non-small-cell lung cancer

## Non-squamous non-small cell lung cancer, ALK positive

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/TA670) or
* the [NICE technology appraisal guidance on alectinib](https://www.nice.org.uk/guidance/TA536) or
* the [NICE technology appraisal guidance on ceritinib](https://www.nice.org.uk/guidance/TA500) or
* the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA406) or
* platinum doublet chemotherapy.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/TA670), [alectinib](https://www.nice.org.uk/guidance/TA536) or [ceritinib](https://www.nice.org.uk/guidance/TA500), the only recommended treatment option is the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628) (NHS England policy for follow-up treatment to brigatinib).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA406), recommended treatment options are:

* the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/TA571) or
* the [NICE technology appraisal guidance on ceritinib](https://www.nice.org.uk/guidance/TA395).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA406) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/TA571) or [ceritinib](https://www.nice.org.uk/guidance/TA500), the only recommended treatment option is the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628), recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) (NHS England policy) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628), followed by treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628), followed by treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628) followed by treatment with pemetrexed and carboplatin (NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628) and who have disease progression after follow-up treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, the recommended treatment options are:

* the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA422) or
* the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/ta670).

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA422), the recommended treatment options are:

* the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/ta571) or
* the [NICE technology appraisal guidance on ceritinib](https://www.nice.org.uk/guidance/ta395).

For people who have had initial treatment with platinum doublet chemotherapy followed by treatment in line with the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/ta670), or treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA422) followed by the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/ta571) or [ceritinib](https://www.nice.org.uk/guidance/ta395), recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).